{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-28T16:39:40.008576+00:00","company":{"ticker":"CALC","cik":1534133,"company_name":"CalciMedica, Inc."},"pagination":{"limit":100,"returned":70,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"CalciMedica, Inc.","detail":"merger","count":1,"first_seen":"2022-11-22T23:59:59+00:00","last_seen":"2022-11-22T23:59:59+00:00","evidence_fact_ids":[194775]},{"display_name":"Graybug Vision, Inc.","detail":"notes_offering","count":1,"first_seen":"2023-02-16T23:59:59+00:00","last_seen":"2023-02-16T23:59:59+00:00","evidence_fact_ids":[178750]},{"display_name":"Graybug, CalciMedica and Camaro Merger Sub, Inc.","detail":"merger","count":1,"first_seen":"2023-02-16T23:59:59+00:00","last_seen":"2023-02-16T23:59:59+00:00","evidence_fact_ids":[178751]}],"lender":[{"display_name":"Avenue Venture Opportunities Fund II, L.P.","detail":"credit_facility","count":1,"first_seen":"2025-03-05T23:59:59+00:00","last_seen":"2025-03-05T23:59:59+00:00","evidence_fact_ids":[131072]}],"ma_counterparty":[{"display_name":"CalciMedica, Inc.","detail":"change_of_control","count":1,"first_seen":"2023-03-22T23:59:59+00:00","last_seen":"2023-03-22T23:59:59+00:00","evidence_fact_ids":[170288]}]},"facts":[{"fact_type":"earnings_release","fact_key":"13c6694fd9fdcaa0a8a3a76f7d429410232750bc","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2026-05-12T11:00:16+00:00","payload":{"eps_text":"$0.31 per basic share and $0.30 per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net income was $5.0 million","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-12","result_type":"reported_results","revenue_text":null},"claim":"CalciMedica, Inc. reported first quarter ended March 31, 2026 results: net income Net income was $5.0 million, EPS $0.31 per basic share and $0.30 per diluted share.","evidence_excerpt":"Net income was $5.0 million, or $0.31 per basic share and $0.30 per diluted share, for the three months ended March 31, 2026, compared to a net loss of $5.0 million, or $0.36 per basic","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-26-218134","anchor_url":"https://secwatch.observer/filing/0001193125-26-218134#claim-13c6694fd9fdcaa0a8a3a76f7d429410232750bc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312526218134/0001193125-26-218134-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"657252b836158171a45e88195c1980502dc12fc5","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2026-03-18T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2026-09-14","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-03-16","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"CalciMedica, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"March 16, 2026, the Company received a notice from Nasdaq that the Company is not in compliance with Nasdaq’s Listing Rule 5550(a)(2), as the minimum bid price of the Company’s common stock had been below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days following the date of the notice, or until September 14, 2026, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the minimum bid price of the Company’s common stock must meet or exceed $1.00 per shar","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-114096","anchor_url":"https://secwatch.observer/filing/0001193125-26-114096#claim-657252b836158171a45e88195c1980502dc12fc5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312526114096/0001193125-26-114096-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"d7211007a4b66380913e5fa5d03a3c694c152b93","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2026-03-18T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2026-09-09","deficiency_type":"market_value","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-03-13","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(b)(2)","5550(b)(1)","5550(b)(3)"],"rules_cited_in_text":true},"claim":"CalciMedica, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5550(b)(1), 5550(b)(3)).","evidence_excerpt":"March 13, 2026, CalciMedica, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5550(b)(2), as the market value of listed securities (the “MVLS Requirement”) for the Company’s common stock had been below the minimum MVLS Requirement of $35,000,000 for the last 30 consecutive business days. Nasdaq also noted that the Company does not meet the requirements under Listing Rules 5550(b)(1) and 5550(b)(3). Under Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days following t","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-114096","anchor_url":"https://secwatch.observer/filing/0001193125-26-114096#claim-d7211007a4b66380913e5fa5d03a3c694c152b93","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312526114096/0001193125-26-114096-index.htm"},{"fact_type":"auditor_change","fact_key":"250cc2a8fc97530dbaab0905a683d75f164bb4ee","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2025-06-06T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Baker Tilly US, LLP","disagreement_text":null,"effective_date":"2025-06-03","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"CalciMedica, Inc. engaged Baker Tilly US, LLP as its auditor.","evidence_excerpt":"Audit Committee of the Company's Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company's independent registered public accounting firm effective on June 3, 2025","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-136297","anchor_url":"https://secwatch.observer/filing/0001193125-25-136297#claim-250cc2a8fc97530dbaab0905a683d75f164bb4ee","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312525136297/0001193125-25-136297-index.htm"},{"fact_type":"auditor_change","fact_key":"2c4ed4915bc28cb36e715293ef220da653b45e24","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2025-06-06T23:59:59+00:00","payload":{"action":"resignation","auditor_name":"Moss Adams LLP","disagreement_text":null,"effective_date":"2025-06-03","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Baker Tilly US, LLP"},"claim":"Moss Adams LLP resigned as auditor of CalciMedica, Inc..","evidence_excerpt":"On June 3, 2025, CalciMedica, Inc., (the “Company”) was notified that Moss Adams LLP (“Moss Adams”), the Company’s independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-136297","anchor_url":"https://secwatch.observer/filing/0001193125-25-136297#claim-2c4ed4915bc28cb36e715293ef220da653b45e24","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312525136297/0001193125-25-136297-index.htm"},{"fact_type":"debt_financing","fact_key":"b966acaeacb1b25443b2c81aae5e4cdcb79b29d8","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2025-03-05T23:59:59+00:00","payload":{"counterparty":"Avenue Venture Opportunities Fund II, L.P.","effective_date":"2025-02-28","event":"incurrence","instrument_type":"credit_facility","interest_rate_text":"annual rate equal to the greater of (a) the sum of 5.00% plus the prime rate as","item_codes_triggered":["2.03"],"maturity_text":"September 1, 2028","principal_text":"up to $32,500,000"},"claim":"CalciMedica, Inc. incurred credit facility of up to $32,500,000 with Avenue Venture Opportunities Fund II, L.P. at annual rate equal to the greater of (a) the sum of 5.00% plus the prime rate as maturing September 1, 2028.","evidence_excerpt":"On February 28, 2025 (the “Closing Date”), CalciMedica, Inc. (the “Company”) entered into a Loan and Security Agreement and the Supplement to the Loan and Security Agreement (together, the “Loan Agreement”) with Avenue Venture Opportunities Fund II, L.P. (the “Lender”) and Avenue Capital Management II, L.P., as administrative agent and collateral agent, for growth capital loans in an aggregate principal amount of up to $32,500,000 (the “Loan”), with (i) $10,000,000 funded on the Closing Date (“Tranche 1”), (ii) up to $7,500,000 to be made available to the Company between September 1, 2025 and March 31, 2026, subject to, among other things, the Company’s achievement of certain milestones with respect to certain of its ongoing clinical trials (“Tranche 2”) and (iii) up to $15,000,000 to be made available to the Company between October 1, 2025 and March 31, 2026, subject to, among other things, (a) the Company’s achievement of additional milestones with respect to certain of its ongoing c","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-046225","anchor_url":"https://secwatch.observer/filing/0001193125-25-046225#claim-b966acaeacb1b25443b2c81aae5e4cdcb79b29d8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312525046225/0001193125-25-046225-index.htm"},{"fact_type":"executive_change","fact_key":"f8d2d719f1","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2025-01-14T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-15","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Alan Glicklich was appointed as Class I Director at CalciMedica, Inc..","evidence_excerpt":"On January 13, 2025, the Company’s Board appointed Alan Glicklich, M.D., as a Class I director of the Company, effective as of the Effective Date, with a term of office expiring at the 2027 annual meeting of stockholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-005654","anchor_url":"https://secwatch.observer/filing/0001193125-25-005654#claim-f8d2d719f1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312525005654/0001193125-25-005654-index.htm"},{"fact_type":"executive_change","fact_key":"fc5f8f6b2a","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2025-01-14T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-01-15","interim":false,"role":"Director and Chair of Audit Committee","role_category":"director","successor_name":"Alan Glicklich","successor_named":true},"claim":"Eric Bjerkholt resigned as Director and Chair of Audit Committee at CalciMedica, Inc..","evidence_excerpt":"On January 10, 2025, Eric Bjerkholt tendered his resignation as a member of the board of directors (the “Board”) of CalciMedica, Inc., a Delaware corporation (the “Company”) and as Chair and a member of the audit committee of the Board, effective as of January 15, 2025 (the “Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-005654","anchor_url":"https://secwatch.observer/filing/0001193125-25-005654#claim-fc5f8f6b2a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312525005654/0001193125-25-005654-index.htm"},{"fact_type":"executive_change","fact_key":"e34358b13e","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2024-11-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Stephen Bardin was appointed as Chief Financial Officer at CalciMedica, Inc..","evidence_excerpt":"the Company’s board of directors (the “Board”) appointed Stephen Bardin as the Company’s Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer effective as of the Effective Date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-253754","anchor_url":"https://secwatch.observer/filing/0001193125-24-253754#claim-e34358b13e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312524253754/0001193125-24-253754-index.htm"},{"fact_type":"executive_change","fact_key":"dd5f8e442a","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2024-11-08T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"interim Chief Financial Officer","role_category":"cfo","successor_name":"Stephen Bardin","successor_named":true},"claim":"Dan Geffken resigned as interim Chief Financial Officer at CalciMedica, Inc..","evidence_excerpt":"Dan Geffken tendered his resignation as interim Chief Financial Officer, principal financial officer and principal accounting officer of CalciMedica, Inc.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-253754","anchor_url":"https://secwatch.observer/filing/0001193125-24-253754#claim-dd5f8e442a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312524253754/0001193125-24-253754-index.htm"},{"fact_type":"earnings_release","fact_key":"25821f1260f103955542ecdf2a325aa117bc1624","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"eps_text":"$0.01 per share (basic and diluted)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$0.1 million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-13","result_type":"reported_results","revenue_text":null},"claim":"CalciMedica, Inc. reported the first quarter ended March 31, 2024 results: net income $0.1 million, EPS $0.01 per share (basic and diluted).","evidence_excerpt":"With the impact of a $5.6 million non-cash gain from the fair value adjustment of the warrant liability, net income was $0.1 million, or $0.01 per share (basic and diluted) for the three months March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-058730","anchor_url":"https://secwatch.observer/filing/0000950170-24-058730#claim-25821f1260f103955542ecdf2a325aa117bc1624","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000095017024058730/0000950170-24-058730-index.htm"},{"fact_type":"auditor_change","fact_key":"d36f9d935d1fe4ee76f5011dfe2e566d1a45780c","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2024-04-10T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Moss Adams LLP","disagreement_text":null,"effective_date":"2024-04-05","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"CalciMedica, Inc. engaged Moss Adams LLP as its auditor.","evidence_excerpt":"(b) Engagement of New Independent Registered Public Accounting Firm On April 5, 2024, the Audit Committee approved the engagement of Moss Adams LLP (“Moss Adams”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. On April 9, 2024, Moss Adams was engaged as the Company’s independent registered public accounting firm.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-092036","anchor_url":"https://secwatch.observer/filing/0001193125-24-092036#claim-d36f9d935d1fe4ee76f5011dfe2e566d1a45780c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312524092036/0001193125-24-092036-index.htm"},{"fact_type":"auditor_change","fact_key":"603556de78e3b4f11c602916efa1d9f74376c44d","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2024-04-10T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"Ernst & Young LLP","disagreement_text":null,"effective_date":"2024-04-05","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Moss Adams LLP"},"claim":"CalciMedica, Inc. dismissed Ernst & Young LLP as its auditor.","evidence_excerpt":"(a) Dismissal of Independent Registered Public Accounting Firm On April 5, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of CalciMedica, Inc. (the “Company”) approved the dismissal of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm. On April 5, 2024, EY was informed that they were dismissed. EY’s audit reports on the Company’s financial statements for the years ended December 31, 2023 and 2022 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-092036","anchor_url":"https://secwatch.observer/filing/0001193125-24-092036#claim-603556de78e3b4f11c602916efa1d9f74376c44d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312524092036/0001193125-24-092036-index.htm"},{"fact_type":"earnings_release","fact_key":"3552e9c8cd6fb521c34c4252ffa8629e7e6b14f9","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2024-03-28T23:59:59+00:00","payload":{"eps_text":"$7.66 per share (basic and diluted)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$34.4 million, or $7.66 per share (basic and diluted)","period_text":"the year ended December 31, 2023","report_date":"2024-03-28","result_type":"reported_results","revenue_text":null},"claim":"CalciMedica, Inc. reported the year ended December 31, 2023 results: net income $34.4 million, or $7.66 per share (basic and diluted), EPS $7.66 per share (basic and diluted).","evidence_excerpt":"Net loss was $34.4 million, or $7.66 per share (basic and diluted) for the year ended December 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-037609","anchor_url":"https://secwatch.observer/filing/0000950170-24-037609#claim-3552e9c8cd6fb521c34c4252ffa8629e7e6b14f9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000095017024037609/0000950170-24-037609-index.htm"},{"fact_type":"material_agreement","fact_key":"9e53f0d737e644bd8d228f906066a899565ec0b7","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2024-01-24T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain accredited investors","effective_date":"2024-01-19","item_codes_triggered":["1.01"],"value_text":"$20.4 million"},"claim":"CalciMedica, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $20.4 million (effective 2024-01-19).","evidence_excerpt":"On January 19, 2024, the Company and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Securities Purchase Agreement”)","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001193125-24-013513","anchor_url":"https://secwatch.observer/filing/0001193125-24-013513#claim-9e53f0d737e644bd8d228f906066a899565ec0b7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312524013513/0001193125-24-013513-index.htm"},{"fact_type":"material_agreement","fact_key":"d84ca4c954c2cb7f30961867ffc354b24be39122","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2024-01-22T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain accredited investors","effective_date":"2024-01-19","item_codes_triggered":["1.01"],"value_text":"upfront gross proceeds from the Private Placement of $20.4 million"},"claim":"CalciMedica, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at upfront gross proceeds from the Private Placement of $20.4 million (effective 2024-01-19).","evidence_excerpt":"On January 19, 2024, CalciMedica, Inc. (the “Company”) and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Securities Purchase Agreement”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-011738","anchor_url":"https://secwatch.observer/filing/0001193125-24-011738#claim-d84ca4c954c2cb7f30961867ffc354b24be39122","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312524011738/0001193125-24-011738-index.htm"},{"fact_type":"earnings_release","fact_key":"b245dc0629680127fcc4fe87a2c569b7d75b5766","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-11-09T23:59:59+00:00","payload":{"eps_text":"$0.82 per share (basic and diluted)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $4.6 million, or $0.82 per share (basic and diluted)","period_text":"the third quarter ended September 30, 2023","report_date":"2023-11-09","result_type":"reported_results","revenue_text":null},"claim":"CalciMedica, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $4.6 million, or $0.82 per share (basic and diluted), EPS $0.82 per share (basic and diluted).","evidence_excerpt":"CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the third quarter ended September 30, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-061514","anchor_url":"https://secwatch.observer/filing/0000950170-23-061514#claim-b245dc0629680127fcc4fe87a2c569b7d75b5766","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000095017023061514/0000950170-23-061514-index.htm"},{"fact_type":"earnings_release","fact_key":"d49daf2f555e9ac4ee8cb5b91ff501d6576aae94","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-08-10T23:59:59+00:00","payload":{"eps_text":"$1.11 per share (basic and diluted)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$6.3 million, or $1.11 per share (basic and diluted)","period_text":"three months ended June 30, 2023","report_date":"2023-08-10","result_type":"reported_results","revenue_text":null},"claim":"CalciMedica, Inc. reported three months ended June 30, 2023 results: net income $6.3 million, or $1.11 per share (basic and diluted), EPS $1.11 per share (basic and diluted).","evidence_excerpt":"Net loss was $6.3 million, or $1.11 per share (basic and diluted), and $25.6 million, or $7.86 per share (basic and diluted), for the three and six months ended June 30, 2023, respectively.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-209160","anchor_url":"https://secwatch.observer/filing/0001193125-23-209160#claim-d49daf2f555e9ac4ee8cb5b91ff501d6576aae94","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523209160/0001193125-23-209160-index.htm"},{"fact_type":"shareholder_vote","fact_key":"63a1ae4258248b4d6809d9a7d0ced96bc3f31d77","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-08-10T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-09","outcome":"passed","proposal_text":"Ratification of the Selection of Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"845","votes_against":"2,269","votes_for":"4,208,835","votes_withheld":null}]},"claim":"CalciMedica, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-08-09 meeting.","evidence_excerpt":"Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s principal independent registered public accounting firm for the fiscal year ending December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-209160","anchor_url":"https://secwatch.observer/filing/0001193125-23-209160#claim-63a1ae4258248b4d6809d9a7d0ced96bc3f31d77","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523209160/0001193125-23-209160-index.htm"},{"fact_type":"shareholder_vote","fact_key":"5c021481f4b71f339d87fc419e852c36425cc698","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-08-10T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-09","outcome":"passed","proposal_text":"Election of Class III Directors","proposal_type":"director_election","results":[{"broker_non_votes":"256,375","subject":"Robert N. Wilson","votes_abstain":null,"votes_against":null,"votes_for":"3,927,499","votes_withheld":"28,075"},{"broker_non_votes":"256,375","subject":"Allan Shaw","votes_abstain":null,"votes_against":null,"votes_for":"3,928,740","votes_withheld":"26,834"}]},"claim":"CalciMedica, Inc. shareholders approved Election of Class III Directors at the 2023-08-09 meeting.","evidence_excerpt":"Proposal 1. Election of Class III Directors The Company’s stockholders elected the two persons listed below as Class III directors, each to serve a three-year term through the Company’s 2026 annual meeting of stockholders and until a successor has been elected and qualified or until earlier resignation or removal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-209160","anchor_url":"https://secwatch.observer/filing/0001193125-23-209160#claim-5c021481f4b71f339d87fc419e852c36425cc698","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523209160/0001193125-23-209160-index.htm"},{"fact_type":"earnings_release","fact_key":"519976273b1fc26488b6ca874b5378c2eb5a8639","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-05-15T23:59:59+00:00","payload":{"eps_text":"$23.43 per share (basic and diluted)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $19.3 million, or $23.43 per share (basic and diluted), for the three months ended March 31, 2023.","period_text":"first quarter ended March 31, 2023","report_date":"2023-05-15","result_type":"reported_results","revenue_text":null},"claim":"CalciMedica, Inc. reported first quarter ended March 31, 2023 results: net income Net loss was $19.3 million, or $23.43 per share (basic and diluted), for the three months ended March 31, 2023., EPS $23.43 per share (basic and diluted).","evidence_excerpt":"Financial Results for the Three Months Ended March 31, 2023: • Cash, Cash Equivalents and Marketable Securities: As of March 31, 2023, CalciMedica had $34.2 million in cash, cash equivalents and short-term investments. • Total Operating Expenses: Total operating expenses were $22.3 million, which included $16.2 million of one-time charges related to accelerated vesting and severance for employees of Graybug Vision, Inc. (Graybug) at the time of the merger with Graybug. • Net Loss: Net loss was $19.3 million, or $23.43 per share (basic and diluted), for the three months ended March 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-144226","anchor_url":"https://secwatch.observer/filing/0001193125-23-144226#claim-519976273b1fc26488b6ca874b5378c2eb5a8639","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523144226/0001193125-23-144226-index.htm"},{"fact_type":"auditor_change","fact_key":"09b9268c4944da81694e802b672bf4559035b75f","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-05-12T23:59:59+00:00","payload":{"action":"non_reliance","auditor_name":"Ernst & Young LLP","disagreement_text":"concluded that each of (i) the Company's financial statements ... should be restated to correct for errors in the valuation of the convertible promissory notes and warrant liability ... and accordingly should no longer be relied upon","effective_date":"2023-05-08","item_codes_triggered":["4.02"],"non_reliance_signal":"restatement","successor_auditor_name":null},"claim":"CalciMedica, Inc. reported that prior financial statements should not be relied upon.","evidence_excerpt":"concluded that each of (i) the Company’s financial statements as of and for the year ended December 31, 2022, as included in Exhibit 99.1 of the Company’s Form 8-K/A filed on April 4, 2023 (the “Original Report”) with the Securities and Exchange Commission (the “SEC) and (ii) the unaudited pro forma combined financial statements as of and for the year ended December 31, 2022, as included in Exhibit 99.2 of the Original Report (collectively, the “Financial Statements”), should be restated to correct for errors in the valuation of the convertible promissory notes and warrant liability as of December 31, 2022 and accordingly should no longer be relied upon","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-143456","anchor_url":"https://secwatch.observer/filing/0001193125-23-143456#claim-09b9268c4944da81694e802b672bf4559035b75f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523143456/0001193125-23-143456-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"72709d090b1b1a783b502852d6f027a6d5f6bbd1","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-05-05T23:59:59+00:00","payload":{"company_response":"Withdrew appeal; intends to pursue initial listing on Nasdaq","compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"other","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-05-01","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5110(a)","reported_value":null,"rule_numbers":["5110(a)"],"rules_cited_in_text":true},"claim":"CalciMedica, Inc. received a nasdaq delisting notice notice regarding other (rules 5110(a)).","evidence_excerpt":"May 1, 2023, the Company withdrew its request for an appeal of the Staff’s Delist Determination and received a notice from Nasdaq stating that Nasdaq will file a Form 25 Notification of Delisting with the SEC when all internal procedural periods have run. The Company has an initial listing application on file for the listing of the Company’s shares of common stock on Nasdaq and the Company intends to continue to work diligently to satisfy the initial listing requirements and to seek a listing as soon as possible on the Nasdaq Capital Market.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-137097","anchor_url":"https://secwatch.observer/filing/0001193125-23-137097#claim-72709d090b1b1a783b502852d6f027a6d5f6bbd1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523137097/0001193125-23-137097-index.htm"},{"fact_type":"governance_change","fact_key":"72440d4c9c6b3734d50063a5e61396852a8461cd","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-03-20","item_codes_triggered":["5.03"],"summary_text":"Certificate of Amendment filed to change company name from Graybug Vision, Inc. to CalciMedica, Inc."},"claim":"CalciMedica, Inc.: Certificate of Amendment filed to change company name from Graybug Vision, Inc. to CalciMedica, Inc (effective 2023-03-20).","evidence_excerpt":"Immediately prior to the consummation of the Merger, on March 20, 2023, Graybug filed the Certificate of Amendment changing its name from “Graybug Vision, Inc.” to “CalciMedica, Inc.”","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-72440d4c9c6b3734d50063a5e61396852a8461cd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"ma_transaction","fact_key":"e8c00a4027f63511094b4e0459608812e69b55b3","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"change_of_control","closing_date":"2023-03-20","consideration_text":null,"counterparty":"CalciMedica, Inc.","effective_date":"2023-03-20","item_codes_triggered":["2.01","5.01"]},"claim":"CalciMedica, Inc. underwent a change of control involving CalciMedica, Inc. (closed 2023-03-20).","evidence_excerpt":"On March 20, 2023, Graybug, Merger Sub and CalciMedica consummated the transactions contemplated by the Merger Agreement following the Special Meeting.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-e8c00a4027f63511094b4e0459608812e69b55b3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"232329366326f765c4f1ca0bfb9b18a9ca6a04df","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"company_response":"intends to timely request a hearing and apply for OTCQB trading","compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"stockholders_equity","delisting_effective_date":"2023-03-30","exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-03-21","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5110(a), Rule 5405(b)(2)(A), Rule 5405(b)(2)(C)","reported_value":null,"rule_numbers":["5110(a)","5405(b)(2)(A)","5405(b)(2)(C)"],"rules_cited_in_text":true},"claim":"CalciMedica, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5110(a), 5405(b)(2)(A), 5405(b)(2)(C)).","evidence_excerpt":"March 21, 2023, the Company received written notice (the “Notice”) from the Staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Staff has determined that the Company has not complied with the requirements of Nasdaq Listing Rule 5110(a) because the Company did not demonstrate compliance with all of the requirements for initial listing on Nasdaq concurrent with closing the merger transaction. Specifically, the Company did not meet the minimum stockholders’ equity requirement pursuant to Nasdaq Listing Rule 5405(b)(2)(A), the Mar","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-232329366326f765c4f1ca0bfb9b18a9ca6a04df","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"e1f0108ede","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-20","interim":false,"role":"Class II Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Frederic Guerard was appointed as Class II Director at CalciMedica, Inc..","evidence_excerpt":"Frederic Guerard, Pharm.D. 50 Class II Director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-e1f0108ede","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"714ec1d577","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-20","interim":false,"role":"Class III Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Allan Shaw was appointed as Class III Director at CalciMedica, Inc..","evidence_excerpt":"Allan Shaw 59 Class III Director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-714ec1d577","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"91f42665d7","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-20","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Fred Middleton was appointed as Class I Director at CalciMedica, Inc..","evidence_excerpt":"Fred Middleton 73 Class I Director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-91f42665d7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"f7b8abe034","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-20","interim":false,"role":"Chair of the Board and Class III Director","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Robert N. Wilson was appointed as Chair of the Board and Class III Director at CalciMedica, Inc..","evidence_excerpt":"Robert N. Wilson 82 Chair of the Board and Class III Director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-f7b8abe034","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"d870069cac","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-20","interim":false,"role":"Chief Scientific Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Kenneth A. Stauderman was appointed as Chief Scientific Officer at CalciMedica, Inc..","evidence_excerpt":"Kenneth A. Stauderman, Ph.D. 70 Chief Scientific Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-d870069cac","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"9907720555","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-20","interim":false,"role":"Chief Business Officer and Class II Director","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Eric W. Roberts was appointed as Chief Business Officer and Class II Director at CalciMedica, Inc..","evidence_excerpt":"Eric W. Roberts 59 Chief Business Officer and Class II Director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-9907720555","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"be64ea053f","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-20","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Sudarshan Hebbar was appointed as Chief Medical Officer at CalciMedica, Inc..","evidence_excerpt":"Sudarshan Hebbar, M.D. 58 Chief Medical Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-be64ea053f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"e1e192cf16","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-20","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Daniel Geffken was appointed as Interim Chief Financial Officer at CalciMedica, Inc..","evidence_excerpt":"Daniel Geffken, MBA 66 Interim Chief Financial Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-e1e192cf16","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"c2e453a99f","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-20","interim":false,"role":"President and Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Michael J. Dunn was appointed as President and Chief Operating Officer at CalciMedica, Inc..","evidence_excerpt":"Michael J. Dunn, MBA 67 President and Chief Operating Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-c2e453a99f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"834433eb5c","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-20","interim":false,"role":"Chief Executive Officer and Class II Director","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"A. Rachel Leheny was appointed as Chief Executive Officer and Class II Director at CalciMedica, Inc..","evidence_excerpt":"A. Rachel Leheny, Ph.D. 59 Chief Executive Officer and Class II Director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-834433eb5c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"7f3eeb0c70","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-20","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Eric Bjerkholt was appointed as Class I Director at CalciMedica, Inc..","evidence_excerpt":"Eric Bjerkholt was reappointed to the Company’s board of directors as a Class I director, effective as of the effective time of the Merger.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-7f3eeb0c70","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"c24460ed4a","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2023-02-28","interim":false,"role":null,"role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Parisa Zamiri was terminated as other_named_officer at CalciMedica, Inc..","evidence_excerpt":"on February 28, 2023, the board of directors of Graybug terminated Parisa Zamiri’s employment in advance of the anticipated closing date of the Merger.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-c24460ed4a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"af9d338f76","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2023-03-20","interim":true,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Daniel Geffken","successor_named":true},"claim":"Robert S. Breuil was terminated as Chief Financial Officer at CalciMedica, Inc..","evidence_excerpt":"each of Frederic Guerard, PharmD., Graybug’s President and Chief Executive Officer, and Robert S. Breuil, Graybug’s Chief Financial Officer, were terminated effective as of the effective time of the Merger.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-af9d338f76","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"c5ad91403f","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2023-03-20","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"A. Rachel Leheny","successor_named":true},"claim":"Frederic Guerard was terminated as President and Chief Executive Officer at CalciMedica, Inc..","evidence_excerpt":"each of Frederic Guerard, PharmD., Graybug’s President and Chief Executive Officer, and Robert S. Breuil, Graybug’s Chief Financial Officer, were terminated effective as of the effective time of the Merger.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-c5ad91403f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"6cdd9b4245","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-03-20","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dirk Sauer resigned as Director at CalciMedica, Inc..","evidence_excerpt":"each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-6cdd9b4245","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"468b68deda","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-03-20","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Julie Eastland resigned as Director at CalciMedica, Inc..","evidence_excerpt":"each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-468b68deda","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"67abac8a62","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-03-20","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Christina Ackermann resigned as Director at CalciMedica, Inc..","evidence_excerpt":"each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-67abac8a62","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"00c890242a","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-03-20","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Christy Shaffer resigned as Director at CalciMedica, Inc..","evidence_excerpt":"each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-00c890242a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"executive_change","fact_key":"36c3f750ef","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-03-20","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Eric Bjerkholt resigned as Director at CalciMedica, Inc..","evidence_excerpt":"each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-076714","anchor_url":"https://secwatch.observer/filing/0001193125-23-076714#claim-36c3f750ef","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a29873a756d9f64f1e73a70d2faabb4f7bde0309","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-03-15","outcome":"passed","proposal_text":"To approve the possible adjournment of the Special Meeting.","proposal_type":"other","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"85,175","votes_against":"1,424,995","votes_for":"12,820,365","votes_withheld":null}]},"claim":"CalciMedica, Inc. shareholders approved To approve the possible adjournment of the Special Meeting. at the 2023-03-15 meeting.","evidence_excerpt":"PROPOSAL 5 \"Possible Adjournment of the Special Meeting Proposal\": To approve the possible adjournment of the Special Meeting. For Against Abstain 12,820,365 1,424,995 85,175","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-071452","anchor_url":"https://secwatch.observer/filing/0001193125-23-071452#claim-a29873a756d9f64f1e73a70d2faabb4f7bde0309","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523071452/0001193125-23-071452-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b9d531187b9ba10b16843625701d245b2278ccc6","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-03-15","outcome":"passed","proposal_text":"To approve the CalciMedica 2023 Employee Stock Purchase Plan.","proposal_type":"equity_plan","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"268,589","votes_against":"943,669","votes_for":"13,118,277","votes_withheld":null}]},"claim":"CalciMedica, Inc. shareholders approved To approve the CalciMedica 2023 Employee Stock Purchase Plan. at the 2023-03-15 meeting.","evidence_excerpt":"PROPOSAL 4 \"The CalciMedica 2023 Employee Stock Purchase Plan Proposal\": To approve the CalciMedica 2023 Employee Stock Purchase Plan. For Against Abstain 13,118,277 943,669 268,589","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-071452","anchor_url":"https://secwatch.observer/filing/0001193125-23-071452#claim-b9d531187b9ba10b16843625701d245b2278ccc6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523071452/0001193125-23-071452-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1a839613d94e03aca577f03e43b7ac6c8d1ece93","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-03-15","outcome":"passed","proposal_text":"To approve the CalciMedica 2023 Equity Incentive Plan.","proposal_type":"equity_plan","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"287,613","votes_against":"1,957,455","votes_for":"12,085,467","votes_withheld":null}]},"claim":"CalciMedica, Inc. shareholders approved To approve the CalciMedica 2023 Equity Incentive Plan. at the 2023-03-15 meeting.","evidence_excerpt":"PROPOSAL 3 \"The CalciMedica 2023 Equity Incentive Plan Proposal\": To approve the CalciMedica 2023 Equity Incentive Plan. For Against Abstain 12,085,467 1,957,455 287,613","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-071452","anchor_url":"https://secwatch.observer/filing/0001193125-23-071452#claim-1a839613d94e03aca577f03e43b7ac6c8d1ece93","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523071452/0001193125-23-071452-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7afca5dae9a4095fd6f013790935bf67e4a30099","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-03-15","outcome":"passed","proposal_text":"To approve the Amended and Restated Certificate of Incorporation.","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"17,935","votes_against":"1,170,391","votes_for":"13,142,209","votes_withheld":null}]},"claim":"CalciMedica, Inc. shareholders approved To approve the Amended and Restated Certificate of Incorporation. at the 2023-03-15 meeting.","evidence_excerpt":"PROPOSAL 2 \"The Amended and Restated Certificate of Incorporation Proposal\": To approve the Amended and Restated Certificate of Incorporation. For Against Abstain 13,142,209 1,170,391 17,935","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-071452","anchor_url":"https://secwatch.observer/filing/0001193125-23-071452#claim-7afca5dae9a4095fd6f013790935bf67e4a30099","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523071452/0001193125-23-071452-index.htm"},{"fact_type":"shareholder_vote","fact_key":"38e6892d4d74c027767ae2f5d650a862310b565c","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-03-15","outcome":"passed","proposal_text":"To approve the issuance of Graybug common stock in the Merger and the resulting change of control under the Nasdaq Rules (Share Issuance Proposal).","proposal_type":"merger_approval","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"15,233","votes_against":"1,160,128","votes_for":"13,155,174","votes_withheld":null}]},"claim":"CalciMedica, Inc. shareholders approved To approve the issuance of Graybug common stock in the Merger and the resulting change of control under the Nasdaq Rules (Share Issuance Proposal). at the 2023-03-15 meeting.","evidence_excerpt":"PROPOSAL 1 \"The Share Issuance Proposal\": To approve the issuance of Graybug common stock in the Merger and the resulting change of control under the Nasdaq Rules. For Against Abstain 13,155,174 1,160,128 15,233","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-071452","anchor_url":"https://secwatch.observer/filing/0001193125-23-071452#claim-38e6892d4d74c027767ae2f5d650a862310b565c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523071452/0001193125-23-071452-index.htm"},{"fact_type":"executive_change","fact_key":"bd62c5f445","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-03-03T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"routine","effective_date":"2023-02-28","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Parisa Zamiri was terminated as Chief Medical Officer at CalciMedica, Inc..","evidence_excerpt":"On February 28, 2023, the Board of Directors of Graybug Vision, Inc. (“Graybug”) determined it to be in Graybug’s best interests to terminate Parisa Zamiri’s employment in advance of the anticipated closing date of the Merger","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-059999","anchor_url":"https://secwatch.observer/filing/0001193125-23-059999#claim-bd62c5f445","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523059999/0001193125-23-059999-index.htm"},{"fact_type":"material_agreement","fact_key":"f7597485839981ca565d533206702a4ce2386bec","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-02-16T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"First Amendment","agreement_type":"merger","counterparty":"Graybug, CalciMedica and Camaro Merger Sub, Inc.","effective_date":"2023-02-10","item_codes_triggered":["1.01"],"value_text":null},"claim":"CalciMedica, Inc. amended First Amendment with Graybug, CalciMedica and Camaro Merger Sub, Inc. (effective 2023-02-10).","evidence_excerpt":"In connection with the Note Purchase Agreement, on February 10, 2023, Graybug, CalciMedica and Camaro Merger Sub, Inc. (“Camaro Merger Sub”) entered into a First Amendment (the “Amendment”) to the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-041092","anchor_url":"https://secwatch.observer/filing/0001193125-23-041092#claim-f7597485839981ca565d533206702a4ce2386bec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523041092/0001193125-23-041092-index.htm"},{"fact_type":"material_agreement","fact_key":"e80c12700914931bed3f47523d9e879f3da6e24c","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-02-16T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Note Purchase Agreement","agreement_type":"notes_offering","counterparty":"Graybug Vision, Inc.","effective_date":"2023-02-10","item_codes_triggered":["1.01"],"value_text":"$2.0 million"},"claim":"CalciMedica, Inc. entered into Note Purchase Agreement with Graybug Vision, Inc. valued at $2.0 million (effective 2023-02-10).","evidence_excerpt":"On February 10, 2023, Graybug Vision, Inc. (“Graybug”) and CalciMedica, Inc. (“CalciMedica”) entered into a note purchase agreement (the “Note Purchase Agreement”) providing for Graybug to make short-term loans (the “Loan” or “Loans”) to CalciMedica up to an aggregate principal amount of $2.0 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-041092","anchor_url":"https://secwatch.observer/filing/0001193125-23-041092#claim-e80c12700914931bed3f47523d9e879f3da6e24c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523041092/0001193125-23-041092-index.htm"},{"fact_type":"executive_change","fact_key":"262cf1edb8","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-02-09T23:59:59+00:00","payload":{"action":"re-appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Eric Bjerkholt was appointed as Class I Director at CalciMedica, Inc..","evidence_excerpt":"Eric Bjerkholt, a current Class II member of the Board, submitted a letter to resign from the Board and was re-appointed as a Class I director, in each case, contingent upon the Closing and effective as of the Effective Time.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-030003","anchor_url":"https://secwatch.observer/filing/0001193125-23-030003#claim-262cf1edb8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523030003/0001193125-23-030003-index.htm"},{"fact_type":"executive_change","fact_key":"b5641467b4","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-02-09T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dirk Sauer resigned as Director at CalciMedica, Inc..","evidence_excerpt":"the Board received letters from Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigning as directors of the Company and as members of the Committees of the Board, contingent upon the Closing and effective as of the Effective Time","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-030003","anchor_url":"https://secwatch.observer/filing/0001193125-23-030003#claim-b5641467b4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523030003/0001193125-23-030003-index.htm"},{"fact_type":"executive_change","fact_key":"01c5ac56d0","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-02-09T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Julie Eastland resigned as Director at CalciMedica, Inc..","evidence_excerpt":"the Board received letters from Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigning as directors of the Company and as members of the Committees of the Board, contingent upon the Closing and effective as of the Effective Time","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-030003","anchor_url":"https://secwatch.observer/filing/0001193125-23-030003#claim-01c5ac56d0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523030003/0001193125-23-030003-index.htm"},{"fact_type":"executive_change","fact_key":"a316681e43","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-02-09T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Christina Ackermann resigned as Director at CalciMedica, Inc..","evidence_excerpt":"the Board received letters from Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigning as directors of the Company and as members of the Committees of the Board, contingent upon the Closing and effective as of the Effective Time","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-030003","anchor_url":"https://secwatch.observer/filing/0001193125-23-030003#claim-a316681e43","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523030003/0001193125-23-030003-index.htm"},{"fact_type":"executive_change","fact_key":"cca8282dc5","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-02-09T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Christy Shaffer resigned as Director at CalciMedica, Inc..","evidence_excerpt":"the Board received letters from Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigning as directors of the Company and as members of the Committees of the Board, contingent upon the Closing and effective as of the Effective Time","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-030003","anchor_url":"https://secwatch.observer/filing/0001193125-23-030003#claim-cca8282dc5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523030003/0001193125-23-030003-index.htm"},{"fact_type":"executive_change","fact_key":"34ae89d30a","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-02-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Chair of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Robert N. Wilson was appointed as Chair of the Board at CalciMedica, Inc..","evidence_excerpt":"Robert N. Wilson will be the Chair of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-030003","anchor_url":"https://secwatch.observer/filing/0001193125-23-030003#claim-34ae89d30a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523030003/0001193125-23-030003-index.htm"},{"fact_type":"executive_change","fact_key":"079e0bd726","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-02-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Allan Shaw was appointed as Director at CalciMedica, Inc..","evidence_excerpt":"unanimously approved the appointment of A. Rachel Leheny, Ph.D., Eric W. Roberts, Robert N. Wilson, Fred Middleton and Allan Shaw, aged 59, 59, 82, 73 and 58, respectively, to serve as members of the Board, contingent upon the Closing and effective as of the Effective Time","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-030003","anchor_url":"https://secwatch.observer/filing/0001193125-23-030003#claim-079e0bd726","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523030003/0001193125-23-030003-index.htm"},{"fact_type":"executive_change","fact_key":"5a7b8cc260","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-02-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Fred Middleton was appointed as Director at CalciMedica, Inc..","evidence_excerpt":"unanimously approved the appointment of A. Rachel Leheny, Ph.D., Eric W. Roberts, Robert N. Wilson, Fred Middleton and Allan Shaw, aged 59, 59, 82, 73 and 58, respectively, to serve as members of the Board, contingent upon the Closing and effective as of the Effective Time","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-030003","anchor_url":"https://secwatch.observer/filing/0001193125-23-030003#claim-5a7b8cc260","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523030003/0001193125-23-030003-index.htm"},{"fact_type":"executive_change","fact_key":"1441bcb5cf","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-02-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Robert N. Wilson was appointed as Director at CalciMedica, Inc..","evidence_excerpt":"unanimously approved the appointment of A. Rachel Leheny, Ph.D., Eric W. Roberts, Robert N. Wilson, Fred Middleton and Allan Shaw, aged 59, 59, 82, 73 and 58, respectively, to serve as members of the Board, contingent upon the Closing and effective as of the Effective Time","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-030003","anchor_url":"https://secwatch.observer/filing/0001193125-23-030003#claim-1441bcb5cf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523030003/0001193125-23-030003-index.htm"},{"fact_type":"executive_change","fact_key":"14a64a4717","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-02-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Eric W. Roberts was appointed as Director at CalciMedica, Inc..","evidence_excerpt":"unanimously approved the appointment of A. Rachel Leheny, Ph.D., Eric W. Roberts, Robert N. Wilson, Fred Middleton and Allan Shaw, aged 59, 59, 82, 73 and 58, respectively, to serve as members of the Board, contingent upon the Closing and effective as of the Effective Time","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-030003","anchor_url":"https://secwatch.observer/filing/0001193125-23-030003#claim-14a64a4717","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523030003/0001193125-23-030003-index.htm"},{"fact_type":"executive_change","fact_key":"0c3dfd1e68","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2023-02-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"A. Rachel Leheny was appointed as Director at CalciMedica, Inc..","evidence_excerpt":"unanimously approved the appointment of A. Rachel Leheny, Ph.D., Eric W. Roberts, Robert N. Wilson, Fred Middleton and Allan Shaw, aged 59, 59, 82, 73 and 58, respectively, to serve as members of the Board, contingent upon the Closing and effective as of the Effective Time","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-030003","anchor_url":"https://secwatch.observer/filing/0001193125-23-030003#claim-0c3dfd1e68","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523030003/0001193125-23-030003-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"835509d0a675b144259fecaba7e59959669f13da","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2022-12-28T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2023-06-26","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2022-12-27","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5450(a)(1)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"CalciMedica, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"December 27, 2022, Graybug Vision, Inc. (“Graybug” or the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the last 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-22-313722","anchor_url":"https://secwatch.observer/filing/0001193125-22-313722#claim-835509d0a675b144259fecaba7e59959669f13da","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312522313722/0001193125-22-313722-index.htm"},{"fact_type":"material_agreement","fact_key":"51e28ce4bc3217d76d219b7f5bdb79e21747c298","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2022-11-22T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement and Plan of Merger and Reorganization","agreement_type":"merger","counterparty":"CalciMedica, Inc.","effective_date":"2022-11-21","item_codes_triggered":["1.01"],"value_text":null},"claim":"CalciMedica, Inc. entered into Agreement and Plan of Merger and Reorganization with CalciMedica, Inc. (effective 2022-11-21).","evidence_excerpt":"On November 21, 2022, Graybug Vision, Inc., a Delaware corporation (“ Graybug ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with CalciMedica, Inc., a Delaware corporation (“ CalciMedica ”), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for serious inflammatory diseases with high unmet need, and Camaro Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Graybug (“ Merger Sub ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-22-290244","anchor_url":"https://secwatch.observer/filing/0001193125-22-290244#claim-51e28ce4bc3217d76d219b7f5bdb79e21747c298","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312522290244/0001193125-22-290244-index.htm"},{"fact_type":"earnings_release","fact_key":"311f0cd1eceba1f4e2481e7ed1b4e346bad3e541","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2022-11-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$28.2 million","period_text":"the nine months ended September 30, 2022","report_date":"2022-11-10","result_type":"reported_results","revenue_text":null},"claim":"CalciMedica, Inc. reported the nine months ended September 30, 2022 results: net income $28.2 million.","evidence_excerpt":"Net loss for the nine months ended September 30, 2022 was $28.2 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-22-282783","anchor_url":"https://secwatch.observer/filing/0001193125-22-282783#claim-311f0cd1eceba1f4e2481e7ed1b4e346bad3e541","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312522282783/0001193125-22-282783-index.htm"},{"fact_type":"earnings_release","fact_key":"aa7b6f0f2a4194d906fbd11f63a6264d20779881","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2022-11-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$9.8 million","period_text":"the quarter ended September 30, 2022","report_date":"2022-11-10","result_type":"reported_results","revenue_text":null},"claim":"CalciMedica, Inc. reported the quarter ended September 30, 2022 results: net income $9.8 million.","evidence_excerpt":"Net loss for the quarter ended September 30, 2022 was $9.8 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-22-282783","anchor_url":"https://secwatch.observer/filing/0001193125-22-282783#claim-aa7b6f0f2a4194d906fbd11f63a6264d20779881","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312522282783/0001193125-22-282783-index.htm"},{"fact_type":"executive_change","fact_key":"7914274ab0","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2022-04-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-04-13","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dirk Sauer was appointed as Director at CalciMedica, Inc..","evidence_excerpt":"On April 13, 2022 (the “Effective Date”) , the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dirk Sauer, Ph.D, age 62, to serve as a member of the Board to fill the vacancy that was created by the resignation of Dr. Cagle described above.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-22-014650","anchor_url":"https://secwatch.observer/filing/0001564590-22-014650#claim-7914274ab0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000156459022014650/0001564590-22-014650-index.htm"},{"fact_type":"executive_change","fact_key":"725142bb3c","cik":1534133,"ticker":"CALC","company_name":"CalciMedica, Inc.","filed_at":"2022-04-18T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-04-13","interim":false,"role":"Director","role_category":"director","successor_name":"Dirk Sauer","successor_named":true},"claim":"Gerald D. Cagle resigned as Director at CalciMedica, Inc..","evidence_excerpt":"On April 13, 2022, the Board of Directors (the “Board”) of Graybug Vision, Inc. (the “Company”) received a letter from Gerald D. Cagle, Ph.D resigning as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, effective as of that day.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-22-014650","anchor_url":"https://secwatch.observer/filing/0001564590-22-014650#claim-725142bb3c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1534133/000156459022014650/0001564590-22-014650-index.htm"}]}